11:49 AM EDT, 05/28/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) developing novel immunotherapies to transform cancer care, on Tueaday said it reached a clinical supply agreement with Nasdaq-listed BeiGene ( BGNE ) to evaluate the safety and efficacy of Bria-OTS, its next generation immunotherapy, in combination with BeiGene's ( BGNE ) tislelizumab, for the treatment of advanced heavily pretreated metastatic breast cancer.

The limited access Phase 1/2 clinical trial will initially evaluate Bria-OTS alone in breast cancer and later in combination with tislelizumab. BriaCell also plans to evaluate Bria-OTS in prostate and other cancers.

Dr. Del Priore, BriaCell's chief medical officer, said that in randomized Phase 2 and other trials of Bria-IMT, BriaCell immunotherapy has shown survival and clinical benefit in patients with central nervous system (CNS) metastases and after progression on antibody drug conjugates (ADCs). "The Bria-OTS platform is the next generation off-the-shelf therapy with enhanced potency. There is rationale to predict that combining Bria-OTS with tislelizumab may impart additional benefit in this refractory patient population."

BriaCell shares were last seen down $0.04 to $1.90 on the Toronto Stock Exchange.

Price: 1.90, Change: -0.04, Percent Change: -2.06